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Background
Dual antiplatelet therapy represents a cornerstone of the cur-
rent management of acute coronary syndromes. Combining
pharmacological anti-platelet agents, the cyclo-oxygenase
(COX) inhibitor aspirin, with a purine P2Y12 receptor inhibi-
tor, these pharmacological platelet inhibitors are orally loaded
at the time of diagnosis prior to the patient entering the cardiac
catheter laboratory. Until recently, the primary physiological
and pharmacological focus of these agents has been appropri-
ately directed towards their ability to alter the rheology of the
blood; reducing platelet aggregability to attenuate the risk of
stent thrombosis. However, there is now an increasing aware-
ness of the pleotropic properties of anti-platelet therapies, par-
ticularly of the P2Y12 inhibitors, to ameliorate myocardial
ischaemia/reperfusion injury.
Recently, it has been demonstrated that administration of
P2Y12 inhibitors prior to the onset of reperfusion can result
in a significant reduction of infarct size. Interestingly, this
appears to be a class-effect, with a range of chemically distinct
(thienopyridine and non- thienopyridine) P2Y12 inhibitors
demonstrating the same cardioprotective ability to ameliorat-
ing infarct size, provided that an adequate circulating concen-
tration of the inhibitor was present at the moment of reperfu-
sion [1]. The critical difference between thienopyridine and
non-thienopyridine P2Y12 inhibitors concerns the rate of on-
set. The first P2Y12 inhibitor to gain widespread acceptance in
the management of acute coronary syndromes was the
thienopyridine clopidogrel. Clopidogrel, like the other widely
used thienopyridine, prasugrel, requires a significant period of
time to realise P2Y12 inhibition by virtue of the need for he-
patic P450-mediated conversion of the pro-drug into its active
metabolite [2]. The requirement for metabolic conversion is
not a problem with the non-thienopyridine P2Y12 inhibitors
such as Ticagrelor and Cangrelor [2], but the absorption time
from the gut—particularly in patients receiving opiate analge-
sia—will delay the onset of adequate P2Y12 inhibition for
drugs with an oral route of administration [3]. With a rapid
onset of action and the ability to quickly and reliably load the
circulation through intravenous bolus and subsequent infu-
sion, Cangrelor is perhaps the ideal antiplatelet therapy for
use in the emergency management of ST-segment elevation
myocardial infarction, ensuring rapid and effective platelet
inhibition at the time of revascularisation and stent deploy-
ment. The hitherto unexpected (and unrealised) potential clin-
ical advantage of Cangrelor is the amelioration of ischaemia/
reperfusion injury. Not currently targeted as part of routine
clinical management, the excess myocardial cell death
resulting from the restoration of blood and oxygen supply
can contribute up to 50 % of the final infarct size in experi-
mental and clinical studies [4]. Ischaemia/reperfusion injury
therefore represents a clear and currently unmet clinical
need—a need that could be met through re-purposing of a
therapeutic intervention that is already in widespread clinical
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practice, for which an intravenous P2Y12 inhibitor would be
ideally suited.
The mechanism by which platelet P2Y12 inhibition medi-
ates its protection remains unclear, but in this communication,
we provide further evidence that the protection is dependent
upon the presence of blood, and that, unlike other forms of
cardioprotection such as ischaemic conditioning [5], we dem-
onstrate for the first time that P2Y12 inhibitors can result in
significant attenuation of injury of myocardium of animals
with diabetes, an important co-morbidity in the cohort of pa-
tients presenting with an acute coronary syndrome.
Methods
All work was conducted in accordance with the Guidelines on
the Operation of the Animals (Scientific Procedures) Act
1986, published by The Stationery Office (London, UK),
conforming with National Institute of Health Guidelines for
the Care and Use of Laboratory Animals. Cangrelor was kind-
ly supplied by the Medicines Company (NJ, USA), and made
up into solution in normal saline.
Ex-Vivo Mouse Heart Perfusion
Male C57BL6 mice (3–4 months of age, 20–30 g weight)
were anaesthetized with an intra-peritoneal injection of
60 mg/kg pentobarbitone. The heart was harvested via a
para-medial thoracotomy and rapidly transferred to a dissec-
tion dish filled with ice cold Krebs–Henseleit buffer and the
aorta cannulated with a 21-gauge cannula. The heart was
transferred and retrogradely perfused on a Langendorff appa-
ratus, using a modified Krebs–Henseleit buffer (concentra-
tions in mmol/L: NaCl 118.5, NaHCO3 25, glucose 11, KCl
4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2 1.8) at 80 mmHg pres-
sure. Each Langendorff perfused mouse heart was randomly
assigned to one of the reperfusion protocols, with the reperfu-
sion perfusate fortified with either NaCl vehicle (control) or
20, 200 or 400 nmol/L Cangrelor, for the duration of reperfu-
sion. All hearts are stabilized for 20 min prior to being sub-
jected to 35 min global, normothermic (37.0±0.2 °C) ischae-
mia and 30 min reperfusion prior to determination of infarct
size by triphenyl tetrazolium chloride (TTC) staining as de-
scribed below.
In-Vivo Mouse Ischaemia/Reperfusion
C57BL6male mice (age/weight characteristics as above) were
anaesthetized by intraperitoneal injection with a combination
of ketamine, xylazine and atropine (0.01 ml/g) to produce
final concentrations of 10 mg/ml, 2 mg/ml and 0.06 mg/ml
respectively, and the body temperature maintained at 37 °C.
The external jugular vein and carotid artery were isolated and
cannulated for drug administration and mean arterial blood
pressure (MABP) measurement, respectively. A tracheotomy
was performed for artificial respiration at 120 strokes/min and
200 μl tidal volume using a rodent Minivent (type 845; Har-
vard Apparatus, Kent, UK) and supplemental oxygen sup-
plied. A limb lead I electrocardiogram (ECG, LabChart, AD
Instruments, UK) was recorded. A left anterior thoracotomy
and a chest retractor were used to expose the heart. Ligation of
the left anterior descending (LAD) coronary artery was per-
formed using an 8/0 prolene monofilament polypropylene su-
ture. Successful LAD coronary artery occlusion was con-
firmed by the presence of ST-segment elevation on ECG and
a decrease in MABP. Ischaemic conditioning was used as a
positive control, comprising of a single cycle of 5 min ischae-
mia and 5 min reperfusion was effected by temporary LAD
ligation. All hearts were subjected to 35min injurious regional
ischaemia, followed by 2 h reperfusion. Ten minutes prior to
the onset of reperfusion, the animals were treated with an
intravenous 10 min bolus infusion of either vehicle (normal
saline) or Cangrelor (60 μg/kg) followed by a continuous
infusion of either the vehicle or Cangrelor (6 μg/kg/min) upon
the onset and for the duration of reperfusion. At the end of the
reperfusion, the heart was isolated, the aortic root was cannu-
lated and infarct size and risk zone determined by TTC and
Evans blue staining respectively, as described below.
In-Vivo Rat Ischaemia/Reperfusion
Male diabetic Goto-Kakizaki rats (3–4 months of age,
250–300 g, University College London, UK) were used
in this study. Once anesthetized with sodium pentobar-
bital (50 mg/kg i.p.), the rats were intubated and venti-
lated with a Harvard ventilator (70 strokes/min, tidal
volume: 8–10 ml/kg). Body temperature was maintained
at 37±1 °C by means of a rectal probe thermometer
attached to a temperature control system (CMA450).
Once the animal was stable, a left lateral thoracotomy
was performed to expose the heart and a 6-0 suture
placed around the LAD. The suture was tightened using
a loop system to create an LAD occlusion and regional
ischaemia which was confirmed by ST elevation on
ECG and blanching of the myocardium. Following
30 min of ischaemia, the myocardium was reperfused
for 2 h. As in the mouse protocol described above,
the rats were randomly allocated into vehicle control
or Cangrelor treatment groups. Cangrelor was adminis-
tered as a bolus infusion (60 μg/kg) 10 min before
reperfusion, followed by continuous infusion (6 μg/kg/
min) for the whole of the reperfusion period. At the end
of reperfusion, the heart was excised and the aorta can-
nulated for identification of risk zone (Evans blue dye)
and determination of infarct size by TTC staining as
described below.
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Determination of Infarct Size
For in-vivo regional ischaemia experiments, at the end of re-
perfusion, the heart was excised and aorta cannulated to flush
the coronary circulation of blood and the LAD then perma-
nently occluded and the heart then perfused with 0.5 % Evans
blue dye to delineate the area at risk (AAR).
Mouse hearts from in-vivo experiments were infused with
TTC (prior to Evans blue staining) via the aortic cannula, and
then frozen and sliced (6–10 slices perpendicular to long axis).
For ex-vivo mouse hearts with global ischaemia the entire left
ventricle represents the area at risk, and Evans blue infusion was
unnecessary. Rat hearts were first frozen, sliced and then incu-
bated in TTC at 37 °C. TTC stained hearts were then transferred
to 10 % neutral buffer formalin for 2 h at room temperature to
stabilize the staining. The AAR and infarct size were determined
by computerized planimetry performed with the National Insti-
tutes of Health (NIH) software Image (Bethesda, MD, USA).
The AAR was expressed as a percentage of the left ventricle
and the infarct size was expressed as a percentage of the AAR.
Statistical Analysis
Data are shown as mean±SEM. Pairwise comparisons were
made by Student’s t-test. One-way ANOVAwas followed by
post-test analysis using the Tukey test for multiple compari-
sons. Two-way ANOVA was carried out followed by
Bonferroni correction to test for significance when performing
multiple comparisons between different groups. P<0.05 was
considered significant.
Results
Cangrelor is Protective In-Vivo, But Not Ex-Vivo
To determine whether Cangrelor is protective against injurious
ischaemia/reperfusion in mice, we studied Cangrelor use in
both the ex-vivo and in-vivo setting. As previously demonstrat-
ed in a number of different animal models [1, 6, 7], we found
that Cangrelor was significantly protective in the murine heart,
in-vivo, when administered at the time of reperfusion.
Cangrelor attenuated the final infarct size equivalent to that
seen following ischaemic preconditioning (52±5 % in control
hearts versus 28±6 % with cangrelor and 25±1 % for ischae-
mic preconditioning, p<0.05, Fig. 1a). This protection was
dependent upon the presence of blood, as protection observed
in the ex-vivo, crystalloid-perfused setting was not reciprocat-
ed. To confirm this effect we further undertook a dose response
curve. A cangrelor infusion of 6 μg/kg/min is equivalent to a
final blood concentration of 200 nmol/L, but we found no ev-
idence of protection in the isolated heart over a dose-response
range of 20–400 nmol/L (39±3 %, 41±3 %, 36±3 % and 44±
5 % for control, 20, 200 and 400 nmol/L Cangrelor respective-
ly, p=0.5642, Fig. 1b). Cangrelor was also not protective in
crystalloid-perfused rabbit hearts [1], but only a single dose
was studied. Here we extend that observation to a second spe-
cies and a wide range of concentrations.
Cangrelor is Protective in the Diabetic Myocardium
We have previously demonstrated that the threshold for isch-
aemic conditioning is significantly elevated in diabetic myo-
cardium [5], requiring a more robust ischaemic conditioning
stimulus in order to overcome the nascent resistance to
cardioprotective signalling that results from chronic exposure
to hyperglycaemia and altered insulin resistance [5]. To deter-
mine whether Cangrelor would still result in cardioprotection
under these circumstances, we administered Cangrelor at the
time of reperfusion to Goto-Kakizaki rats, a lean type 2 dia-
betic rat derived from the Wistar rat strain [8]. At the drug
infusion rates used, which is relevant to human clinical dos-
ing, Cangrelor resulted in a significant attenuation of infarct
size compared to the vehicle-treated size (20±2 %) compared
to vehicle-treated control diabetic hearts (33±6 %, p<0.05,
Fig. 1c). There was no significant difference in the peri-
procedural blood glucose level between groups (26.4 versus
22.9 mmol/L in control and Cangrelor groups respectively).
Discussion
Here we demonstrate that cangrelor is not protective in an ex-
vivo, non-blood perfusedmurinemodel of ischaemia/reperfusion
injury, but is strongly protective in-vivo. This is the first demon-
stration of the cardioprotective effect of a P2Y12 inhibitor in
mouse—indicating that it would be possible to tease out the
mechanism of this protection using transgenic/knockout models.
Given the apparent dependence upon the presence of blood, it
would seem logical to propose that the cardioprotective effect of
cangrelor is dependent on platelets and likely the platelet P2Y12
receptor, an argument given additional weight by previous obser-
vations that chemically distinct P2Y12 inhibitors such as
clopidogrel have similar cardioprotective properties [1]. The pro-
tection against infarction does not appear to be the direct result of
blocked aggregation as a number of signal transduction inhibitors
blocked cangrelor’s protection but did not restore the ability of
the platelets to aggregate [1]. We would therefore propose that
future work into this highly desirable Bside effect^ of P2Y12
inhibitors—namely the pleotropic attenuation of ischaemia/
reperfusion injury, asmanifest by a significant reductionof infarct
size—should seek to concentrate on identifying cangrelor’s target
in the blood (presumably platelet activation) and that target’s role
in the evolution of myocardial injury.
In this communication, we also demonstrate that, un-
like other forms of cardioprotection such as ischaemic
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conditioning, cangrelor-mediated protection can be seen in
diabetic myocardium. That this is seen when administering
cangrelor at a clinically relevant, anti-platelet dose, is of great
encouragement: in the face of a predicted impending explo-
sion in the prevalence of diabetes within the general popula-
tion, the management of ischaemic heart disease is set to be-
come ever more challenging, and continuation of the recent
historical trend of improving cardiovascular outcomes from
coronary artery disease is likely to become ever more difficult.
Our finding indicates that current therapy with a P2Y12
blocker has the potential to exert an anti-infarct effect in the
diabetic population undergoing PCI provided timely treatment
is administered. An understanding of the fundamental similar-
ities and differences between the protective mechanisms of
classical cardioprotective strategies, such as ischaemic condi-
tioning, and the novel cardioprotection observed following
cangrelor administration should help to elucidate additional
pharmacological targets to further improve patient outcomes,
particularly in those patients with co-morbidities such as
diabetes.
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Fig. 1 The effect of Cangrelor on
infarct size in: a mouse in-vivo
model; b mouse ex-vivo model
and c the diabetic Goto-Kakizaki
in-vivo model. Each bar
represents n=4–5 animals per
group. For in-vivo experiments,
Cangrelor was administered as a
single 60 mg/kg bolus 10 min
prior to the onset of reperfusion,
followed by a 6 mg/kg/min
infusion for the whole reperfusion
period; *p<0.05 treatment versus
respective saline vehicle control
group. For the ex-vivo
experiment, the Cangrelor dosing
regime is as indicated, with the
drug present throughout the
reperfusion period. IPC =
Ischaemic Preconditioning (1×
cycle of 5 min regional ischaemia,
5 min reperfusion)
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